Close

Novo Nordisk (NVO) Announces Semaglutide Received Positive 16-0 vote in Favour of Approval from FDA Advisory Committee

October 18, 2017 5:31 PM EDT Send to a Friend
Novo Nordisk (NYSE: NVO) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login